Cipiram

Cipiram Medicine

Contraindications

Hypersensitivity (including to penicillins, carbopenems, and other cephalosporins).

Incompatibilities

Compatible with saline solution, Ringer's solution, 5 and 10% glucose solution, 5% fructose solution, 6% glucose solution mixed with 0.9% sodium chloride solution.

Pharmaceutical form

Dispersible tablet

Undesirable effects

Nausea, vomiting, diarrhea, transient increase in the activity of hepatic transaminases, leukopenia, neutropenia, transient increase in the concentration of urea and creatinine in the blood plasma, pain and phlebitis at the injection site, allergic reactions (skin rash, itching, drug fever, etc.).

Therapeutic indications

Infections of the upper and lower urinary system, skin and soft tissues, pneumonia, lung abscess, pleural empyema, septicemia, bacteremia, infections in patients with neutropenia and weakened immunity.

Pharmacotherapeutic group

  • Cephalosporins

Pharmacodynamic properties

Highly effective against Gram-positive and gram-negative aerobic and anaerobic microorganisms: E. coli, Salmonella spp., Shigella spp., Proteus mirabilis, Proteus vulgaris, Providencia, Morganella morganii, Citrobacter freundii, Klebsiella oxytoca, Serratia spp., Enterobacter spp., Haemophilus influenzae, Neisseria spp., Moraxella catarrhalis, Streptococcus spp. (including St. pneumoniae), Staphylococcus spp., Peptostreptococcus spp., Clostridium perfringens, Ps.aeruginosa. As a representative of the 4th generation of cephalosporins, it is resistant to the action of known beta-lactamases.

Pharmacokinetic properties

When administered intravenously, it is stored in the blood at a therapeutic concentration for 12 hours. It penetrates well into the tissues and fluids (except for the spinal cord) of the body.

Name of the medicinal product

Cipiram

Qualitative and quantitative composition

Cefpirome

Dosage (Posology) and method of administration

In / in jet or drip. The dosage and method of administration are selected individually, depending on the severity of the infection, its location and the state of kidney function. Usually, 1 g is administered every 12 hours for infections of the urinary system, skin or soft tissues, 1-2 g for respiratory organs, 2 g for septicemia, bacteremia, and patients with neutropenia. In patients with impaired renal function, the dose depends on the creatinine Cl: 5-20 ml / min-0.5-1 g / day (once), 20-50 ml/min-0.5-1 g 2 times a day, for patients on hemodialysis, the daily dose is 0.5 g, in addition, after each procedure, an additional 0.25 g is administered.